https://www.selleckchem.com/products/gdc-0032.html
Treatment of murine meningiomas with anti-CSF1/CSF1R, but not programmed cell death receptor 1 (PD-1), mAbs abrogate tumor growth. RNA-seq and mass cytometry analyses reveal a myeloid cell reprogramming with limited effect on T cells in the tumor microenvironment. CSF1 plasma levels are significantly elevated in human patients and CSF1R is highly expressed on CD163 + macrophages within the human tumor microenvironment. Our findings suggests that anti-CSF1/CSF1R antibody treatment may be an effective normalization cancer immunotherapy f
Like
Comment
Share
